SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.
For other questions, please call Member Services at the number on the back of your member ID card.
A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).
Benefit reminder and Prior Authorization Update for Spravato
Attention: Behavioral health ProvidersEffective Date: January 1, 2021Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.Call to action: Texas Children’s Health Plan (TCHP) aligns with the Health and Human Services Commission (HHSC) on the revised prior authorization criteria for Spravato (Esketamine). Effective January 1, 2021, HHSC will revise the Medicaid and CHIP prior authorization criteria for Spravato (Esketamine).
Spravato (Esketamine) is currently used for treatment-resistant depression (TRD). Effective January 1, it will also be a benefit for the treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.
Esketamine (Spravato) is available only as a medical benefit and may be distributed through specialty pharmacy providers with dates of service on or after July 1, 2020. Providers/health care settings, pharmacies, and members must be certified and/or enrolled in the in the Spravato Risk and Evaluation Mitigation Strategy (REMS) program.
References:Outpatient Drug Services HandbookTMHP notice dated June 5, 2020How this impacts providers: Patients must meet the following requirements for approval of therapy:
Be 18 years of age or older
Have a diagnosis of MDD (diagnosis code F320, F321, F322, F324, F325, F329, F330, F331, F332, F3340, F3341, F3342 or F339)
Have a prescriber’s evaluation show suicidal ideation with intent, or the person needs acute psychiatric hospitalization due to the imminent risk of suicide
Receive Esketamine (Spravato) nasal spray concomitantly with an oral antidepressant agent (Esketamine [Spravato] should not be used as monotherapy)
Have a healthcare provider administer Esketamine (Spravato) under direct observation, and the provider must monitor for at least 2 hours after each treatment session
Have an attestation of baseline scoring of clinical assessment of MDD before starting Esketamine (Spravato) treatment
Not have contraindications to Esketamine (Spravato), such as aneurysmal vascular disease, arteriovenous malformation, or intracerebral hemorrhage
